Should we control the pineal status of patients following brain radiotherapy? [3]

Journal of Neuro-Oncology

Volumn 74, Issue 3, 2005, Pages 335-

  Wion Barbot, Nelly ^a   Berger, Francois ^b   Wion, Didier ^b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ARGIPRESTOCIN; GROWTH HORMONE; MELATONIN; PINEAL BODY HORMONE;

ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; BREAST CARCINOMA; CARCINOGENESIS; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DEMENTIA; DISEASE SEVERITY; ENDOCRINE DISEASE; GROWTH HORMONE DEFICIENCY; HORMONE BLOOD LEVEL; HUMAN; INCIDENCE; LETTER; NEUROPHYSIOLOGY; NEUROPROTECTION; PINEAL BODY DISEASE; SKULL IRRADIATION; TUMOR GROWTH;

BRAIN NEOPLASMS; CRANIAL IRRADIATION; HUMANS; MELATONIN; PINEAL GLAND;

EID: 26844510014     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-0829-4     Document Type: Letter

References (7)

1. TB Johannesen HH Lien KH Hole K Lote 2003 Radiological and clinical assessment of long-term brain tumour survivors after radiotherapy Radiother Oncol 69 169-176 10.1016/S0167-8140(03)00192-0 14643954
2. C Adan J Sainte-Rose M Zucker O Hartmann R Brauner 2001 GH deficiency caused by cranial irradiation during childhood: Factors and markers in young adults J Clin Endocrinol Metab 86 5245-52451 10.1210/jc.86.11.5245 11701685
3. A Brzezinski 1997 Melatonin in humans N Engl J Med 336 186-195 10.1056/ NEJM199701163360306 8988899
4. RM Kostrzewa J Segura-Aguilar 2003 Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection A review. Neurotox Res 5 375-383
5. EJ Lee MY Lee HY Cen YS Hsu TS Wu ST Chen GL Chan 2005 Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemia J Pineal Res 38 42-52 10.1111/ j.1600-079X.2004.00173.x 15617536
6. J Reiter 2004 Mechanisms of cancer inhibition by melatonin J Pinel Res 37 213-214
7. V Anisimov 2003 The role of pineal gland in breast cancer development Crit Rev Oncol Hematol 46 221-234 12791421